This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

ChinaBio® Partnering Forum
Shanghai, China
Save the date for next yearApril 2026

Hyunjin Yang
Director Of Business Development at Ubix Therapeutics
Presenter

Profile

Saving Lives Through Innovations in Targeted Protein Degradation (TPD) Therapeutics. Ubix Therapeutics is a clinical-stage biotechnology company with comprehensive capabilities in TPD therapeutics, spanning from discovery to clinical studies. Our proprietary TPD platform technology, Degraducer®, harnesses the body’s natural protein degradation machinery to eliminate diseased proteins, achieving near-complete inactivation of disease-causing pathways. We have established a robust, wholly owned and partnered degrader pipeline focused on targeted and immuno-oncology areas. Our wholly owned programs include: • UBX-303-1, a Phase 1-stage, potential best-in-class BTK degrader for treating relapsed or refractory B-cell malignancies. • UBX-106, a preclinical-stage, potential first-in-class SHP2 degrader designed to treat a broad spectrum of MAPK signaling-driven solid tumors. Additionally, the IND-enabling study for UBX-103, AR degrader program which was out-licensed to Yuhan in July 2024, is currently underway. We believe our degrader programs can effectively address a broad range of drug resistance mutations and overcome residual activation of disease-causing signaling pathways. Our growing pipeline also includes programs targeting difficult-to-address proteins and the development of degrader-antibody conjugates. For more information, please visit http://en.ubixtrx.com/ or contact us at info@ubixtrx.com.

Agenda Sessions

  • Oncology: Ubix Therapeutics

    16:15